^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    temsirolimus

    i
    Other names: CCI 779, Cell cycle inhibitor-779, CCI-779, NSC-683864, NSC 683864, rapamycin analog CCI-779, CCI779, NSC683864
    Company:
    Generic mfg.
    Drug class:
    mTOR inhibitor
    Related drugs:
    11d
    Dual inhibition of mTOR and HSP90 enhances cisplatin efficacy and overcomes resistance in ovarian cancer. (PubMed, Cell Death Dis)
    Accordingly, the combination of ganetespib (an HSP90 inhibitor) and temsirolimus (a FDA approved-mTOR inhibitor) with cisplatin synergistically reduced colony formation and microtissues cell growth in vitro by increasing DNA-damage and apoptosis and in vivo enhancing mouse survival. Notably, all these data were confirmed also in Pt-resistant Non Small Cell Lung Cancer models. Collectively, our findings identify a promising new antitumor strategy for the treatment of Pt-resistance in cancer patients.
    Journal
    |
    RPS6 (Ribosomal Protein S6) • DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1) • HSF1 (Heat Shock Transcription Factor 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    |
    cisplatin • temsirolimus • ganetespib (ADX-1612)
    11d
    A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours (clinicaltrials.gov)
    P2, N=137, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • NF1 (Neurofibromin 1)
    |
    EGFR mutation • PTEN mutation
    |
    sunitinib • temsirolimus
    14d
    The potential of mitochondrial permeability transition-driven necrosis-related genes in prognostic evaluation of colorectal cancer patients. (PubMed, Front Oncol)
    Immunoassays revealed that high-risk patients had 9 elevated immune checkpoints, while low-risk patients were more susceptible to pazopanib and temsirolimus. Real-time PCR (RT-qPCR) confirmed low levels of CASP7, PRKCB, and ENDOG mRNA in CRC tissues, with no significant difference between LMNB2 and GZMB. These findings highlight 5 MPTDN-associated prognostic genes in CRC, providing insights for individualized treatment and prognosis.
    Journal
    |
    GZMB (Granzyme B) • CASP7 (Caspase 7) • PRKCB (Protein Kinase C Beta) • LMNB2 (Lamin B2)
    |
    pazopanib • temsirolimus
    14d
    GSDME-mediated pyroptosis is essential for the chemotherapeutic effects achieved by combined treatment of temsirolimus and 5-fluorouracil in ovarian carcinoma cells. (PubMed, Am J Transl Res)
    GSDME is the principal executor of spontaneous pyroptosis in ovarian cancer tissues. In chemotherapy employing cell cycle-targeting agents or PI3K-AKT-mTOR pathway inhibitors (alone or in combination) is beneficial, and pyroptosis is an indispensable cell death mechanism. Reactive oxygen species act as a nodal regulator orchestrating pyroptosis, apoptosis, and ferroptosis.
    Journal
    |
    GSDME (Gasdermin E) • GSDMD (Gasdermin D)
    |
    5-fluorouracil • temsirolimus
    15d
    Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    temsirolimus • Ixempra (ixabepilone) • patupilone (EPO 906)
    18d
    TORERO: Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=45, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Unknown status --> Completed
    Trial completion
    |
    Erbitux (cetuximab) • temsirolimus
    19d
    Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, Rapa Therapeutics LLC | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Mar 2028 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    carboplatin • paclitaxel • temsirolimus • sirolimus • RAPA-201
    21d
    A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies (clinicaltrials.gov)
    P2, N=67, Not yet recruiting, Yonsei University
    New P2 trial
    |
    everolimus • temsirolimus
    1m
    Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (clinicaltrials.gov)
    P2, N=720, Recruiting, Canadian Cancer Trials Group | Trial primary completion date: Jan 2026 --> Dec 2026
    Trial primary completion date • Tumor mutational burden • Pan tumor
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • bosutinib • Tukysa (tucatinib) • temsirolimus • axitinib • Erivedge (vismodegib)
    1m
    Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (clinicaltrials.gov)
    P1, N=38, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    PIK3CA mutation
    |
    Avastin (bevacizumab) • oxaliplatin • temsirolimus • pegylated liposomal doxorubicin • leucovorin calcium • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • fluorouracil topical
    2ms
    Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    everolimus • temozolomide • doxorubicin hydrochloride • pazopanib • cyclophosphamide • ifosfamide • irinotecan • temsirolimus • vincristine • daunorubicin • ganitumab (AMG 479)
    5ms
    Myeloperoxidase inhibits prostate cancer progression, suppresses the PI3K/AKT signaling pathway and reshapes the immune microenvironment. (PubMed, Transl Androl Urol)
    Drug sensitivity predictions indicated patients with high MPO expression were more sensitive to PI3K/AKT inhibitors (e.g., temsirolimus), but their TIDE score suggested a potentially lower response to immunotherapy...MPO serves as an independent prognostic marker and its downregulation contributes to tumor growth via PI3K/AKT signaling while influencing the immune microenvironment. These findings suggest MPO as a new target for combined therapeutic strategies based on metabolic intervention.
    Journal • IO biomarker
    |
    MPO (Myeloperoxidase)
    |
    temsirolimus